Thursday, February 7, 2019

A quick note on the resignations at the top of National Australia Bank

The Chairman (Dr Henry) and the CEO (Andrew Thorburn) of National Australia Bank have just resigned following criticism by the Australian Banking Royal Commissioner.

I do not know Andrew Thorburn, but I know Dr Ken Henry well and am proud to count him as a friend.

In February 2016 Jonathan Tepper (of the English research firm Variant Perception) and I spent a week traipsing around the outer suburbs of Sydney checking out property developers, mortgage brokers and even some bank branches.

It was dead easy to find widespread evidence of mortgage fraud. It was pervasive - fraud was the way of doing business. Jonathan Tepper wrote it up in a now infamous report on the state of the Australian property market.

Jonathan Tepper was widely mocked in the Australian press when our findings were published. However the findings we had were confirmed by the evidence put before the recent Royal Commission.

For the record we found that all four Australian banks were problematic but that National Australia Bank was the least bad of a bad lot.

I went to have a chat with Dr Henry who took our findings seriously and began the (admittedly difficult) task of improving the National Australia Bank.

He was open about the difficulties in doing so, open about the incentives both within the bank and outside the bank and was cognoscente how difficult this was going to be. But he started.

I am not trying to defend National Australia Bank. It was the best of a (very) bad lot. But it was still not very good and Dr Henry started the task of making it directionally better.


Anyway come the Royal Commission Dr Henry talked to the Commission in a frank and open way about the problems. It was Dr Henry being Dr Henry: honest, competent, and realistic.

It came off badly. I remember the grilling he got from the Royal Commission and understood what was happening. It was clear that what was required from the Royal Commission was kowtow, rather than honest frank discussion. Dr Henry looked bad even though he was probably the single most reliable and honest witness the banks put up.

The Royal Commissioner made specific findings against Dr Henry and Andrew Thornburn. This surprised me because on my research National Australia Bank was the best of a bad lot, both in absolute level of moral decay and in direction.

The Royal Commissioner I believe misinterpreted the relative honesty of National Australia Bank.

Direct criticism was made of Dr Henry and Andrew Thornburn and today they resigned.

I am not sure that any Australian banker deserved to come out of the Royal Commission unscathed, but in a relative sense injustice has been done. The most honest party at the Royal Commission has paid with their career for their honesty.

I don't think Kenneth Hayne (the Commissioner) has done the country or the cause of banking reform a good job. And that is a pity.

John Hempton

A post script is warranted: one of the key conversations I had with Dr Henry I had in the presence of Rob Shears from Valor Private Wealth.

Rob is a financial planner and a friend of mine.

He has regularly (and appropriately anonymised) told me of the financial condition of prospective clients, many of whom are loaded with inappropriate mortgages on (sometimes multiple) investment properties.

He is a very good window on bad bank underwriting.

Anyway he was in the room when I had a phone conversation.

Today he tweeted this:

One of our clients friends is a bank manager of a NAB branch. Within 48 hours of the phone call you made to Ken a few years ago (I was in your office at the time) there were significant restrictions put on certain investor loans immediately. Ken is honest and competent.

I was unaware at the speed at which NAB acted when reliably informed of bad practices. But it confirms my impression of how NAB (and NAB alone) took our report seriously.

Monday, January 14, 2019

The Myth of Capitalism: Monopolies and the Death of Competition. Jonathan Tepper and Denise Hearn. A review...

The Myth of Capitalism is a polemic about the reduction in competition in many industries in the US. And it starts in an entirely appropriate place.

Dr Dao - a doctor with patients to serve the next day - was "selected" by United Airlines to be removed from an overbooked plane.

As he had patients to tend the next day he did not think he should leave the plane. So the airline sent thugs to bash him up and forcibly removed him.

The video (truly sickening) went viral. But the airline did not apologise. The problem it seems was caused by customer intransigence. 

They apologised after what Tepper and Hearn think was true public revolt, but what I think was more likely the realistic threat to ban United Airlines from China because of the racial undertones underlying that incident.

If a "normal" company sent thugs to brutalise its customers it would go out of business. But United went from strength to strength.

The reason the authors assert was that United has so much market power you have no choice to fly them anyway - and by demonstrating they had the power to kick your teeth in they also demonstrated that they had the power to raise prices. The stock went up pretty sharply in the end.

Oligopoly - extreme market power - not only makes airlines super-profitable. It gives them the licence to behave like complete jerks. 

But what is true of airlines is true of industry after industry in the United States. Hospital mergers have left many towns with one or two hospitals. Health insurance is consolidated to the point where in most states there is only one or two realistic choices. Even the chicken-farming industry is consolidated to the point where the relatively unskilled and non-technical industry makes super-normal profits. Tepper and Hearn have assembled many other examples.

Two other assertions lace this book. Firstly - and somewhat controversially - the authors assert that low levels of competition lead to low levels of innovation (and hence lower levels of economic growth). This is controversial because Silicon Valley produces companies with very little competition (Google for example) that are clearly innovative.

The second assertion is that companies with market power use their power both ways - firstly to raise prices to customers, but just as importantly to squeeze suppliers, especially employees.

Oligopoly and innovation

Peter Thiel (one of the anti-heroes of this book) has long argued that market power and super-normal profits are the goal of innovation and that innovative firms innovate to keep the good times rolling. And indeed this is part of the model of Silicon Valley. Thiel's receives consistent support from economists who receive sponsorship/grants/work from monopolists. Tepper suggests that these economists might be compared to prostitutes - except that would be grossly unfair to prostitutes. 

I am going to add my two-bits worth here. Thiel is almost certainly right in Silicon Valley. Innovation is both the source of and funded by high-levels of market power.

But Thiel is wrong in much of the world. I live in Australia - the land of oligopolies. The Sydney business community is possibly the most conservative business community that size in the world. If you are a businessman here your job is to (largely) to milk the excessive market power that your business has in what is a small and isolated market. Disruption is to be feared and discouraged because it is a threat to the gravy train. This differs a lot from Thiel's world - but I suspect that in many industries oligopolists are innovation phobic. 

Oligopoly and suppliers

Perhaps the biggest contribution this book makes to the policy debate is to examine how market power is used to squeeze suppliers and not just customers. This is - in the authors view - why in this cycle wages have not risen as the economy comes close to full employment. They just think that monopsony employers squeeze wages. They do because of market power - and because of unfair clauses in employment contracts like non-compete clauses. There is an argument for non-compete clauses where staff could walk with intellectual property - but the book notes widespread non-compete clauses in the fast food industry. A non-compete for flipping burgers is just a mechanism that allows employers to suppress wages.

Tepper and Hearn note that wage growth is slower in areas with few employment choices (especially areas with just one large employer in town). The rural-urban wage divide in America is - the author argue - exacerbated by this. 

When you interview Trump voters in rural areas about why they voted for Trump they often state that they think the system is rigged against them. Tepper and Hearn argue that is because the system really is rigged against them.

Low prices and oligopoly

There is a form of American industry that doesn't try to raise prices. Amazon, Costco and above all WalMart are the key example.

Walmart for years used to talk in their conference calls about all the cost savings they were implementing. And analysts would want to put those cost savings into their model as earnings. Walmart would disabuse you of this. Cost savings are passed to customers

By doing this Walmart squeezed competitors until in many places it is the only local supplier of note. But it did this by the pro-market tactic of lower prices.

This doesn't look supportive of the Tepper/Hearn thesis - except that they argue that Walmart and Amazon (but to a much lesser extent Costco) then use the considerable market power they accrue to squeeze their suppliers (especially their workers). Walmart famously pays low wages. Amazon uses veritable armies of lowly paid contractors. 

Market power gives licence to corporate management to behave like jerks, whether it be kicking in the teeth of their customers (United Airways) or paying their workers poverty wages (Walmart).

The Costco counter-example

Costco is almost the only company in this book that comes off well. Sure they win by having lower prices - but they also win by having well paid and happier workers (and much lower staff turnover). Costco management are not jerks. And in that they provide a decent counterexample to management described throughout this book.

But even Costco squeezes suppliers. This example is recent and not in the book. Costco is entering the business of breeding chickens for meat - and it is doing it in a spectacularly large way. Obviously this is not core business. But they came up against the chicken meat oligopoly (discussed in the book) and Costco thought they would win by disrupting their oligopolistic suppliers.

An angry book is not much use to me

Tepper and Hearn have written an angry book. It is angry at the regulators that have allowed non-competitive mergers to happen. It is angry at politicians and lobbyists in the pocket of supernormally profitable corporations.

The solution to the problem in capitalism according to the authors is more capitalism. They want more entrepreneurism, less barriers to entry in companies but also they want regulators to view skeptically (and stop) anti-competitive mergers. They endorse measures against tech companies that stop them leveraging monopolies on one sector into monopolies in another sector. They would have endorsed the break-up of Microsoft into an operating system company and an applications company.

They provide a reasonable agenda for a market-friendly politician or regulator who believes in competition and doesn't want to be on the lobbyist tit. 

All well and good but I have no use for their anger. I am not a regulator or a lobbyist or a politician. And there are plenty of other things in the world to be angry about. 

But that doesn't mean I regret reading the book. I don't. I am a hedge fund manager and my job is to make money for my clients. 

And the simple question I ask about a book like this is "will it help me make money for my clients".

In this case the answer is yes. 

It gave me a few direct clues on how to make money. But I am not going to tell you those. Read the book. 

But it also gave me some useful analytical tools which I will use fairly regularly. That I demonstrate by example.

French fries and (economic) freedom

Lamb Weston - the world's biggest marker of french fries is a minor obsession of mine. Margins have crept up and are now over 17 percent. If you go back 20 years (well before the company was spun out of Conagra) the company business faced gluts and made losses. 

Profitability has been rising for years. Operating margins are now two thirds of Apple. But Apple do cool sophisticated and expensive stuff for those margins. Lamb Weston processes and distributes potatoes.

The business used to be cyclic. There is an article in the New York Times in 1997 about about a glut laying waste to the industry. 

But it doesn't look like that now - and it hasn't for years. 

The market values Lamb Weston at 3.4 times sales. [Ratio is (net debt + market cap)/revenue.]

By contrast Apple - a company that has huge market power and very fat margins - is valued at 2.9 times sales.

To me this looks absurd. The market values wholesale sales of french fries considerably higher than it values Apple's sales.

Apple does a huge amount for its sales. They develop and manufacture sophisticated and groovy devices with sophisticated software. They have redefined corporate cool. And they smell hyper-profitable.

Except that buying potatoes cutting them into french fries, par cooking them, freezing them and distributing them to fast-food chains is valued more highly by the market. (Again my measure is EV to sales but this is true by most measures...)

And it is not as if french fries are high growth either. They grow low single digit - and there are good reasons (mostly health) as to why that should slow too. 

I have to ask myself why shouldn't I short Lamb Weston. Surely competition is going to rip those margins lower at some point.

Tepper and Hearn provide one explanation as to why I should not put on the obvious trade - oligopoly.

And it is pretty clear that they are right. French fries is a super-profitable business.

In conference calls Lamb Weston signal extremely modest expansions in capacity. It is like the many companies who signal in conference calls that they are happy with their market share. They are of course signalling that they are not interested in a price war.

Of course an oligopoly is vulnerable if someone well funded wants to enter the industry. And in a country with true economic freedom that shouldn't he hard. There isn't anything spectacularly technical about making french fries.

That the margin has stayed this high (and indeed grown) is a signal of a lack of economic freedom. Nobody seems able or willing to break the french fry oligopoly - and that has to be in some sense political.

We shouldn't call them "freedom fries". May I propose "economic oppression fries". It seems more accurate.

The politics of the french fry oligopoly

French fries it seems are absurdly profitable. The return on assets is in the teens (which seems kind-of-good in this low return world). Margins keep rising and yet there is no obvious emerging competition.

It may be a good investment even though it looks pretty expensive. But if competition comes Lamb Weston could be a terrible stock.

There has been plenty of consolidation in this industry. Sure many of the mergers shouldn't have been approved by regulators - but they were - and the industry has become oligopolistic.

But this is not a complicated industry - it is not obvious why competition doesn't come. 

Bluntly I really don't have a clue what keeps the competition out.

It could be regulation (and captured regulators). It might be the farmers don't want further entries.

Whatever there is not much policy ground for lowering the cost of french fries. They don't exactly meet public health objectives.

Tepper and Hearn would argue that the oligopoly is used to suppress payments to suppliers - and the main supplier here are Idaho farmers. Usually they would be pretty good at lobbying. But there is another possibility - which is that the oligopoly is super-strong - and some of the excess profits are used to pay over-market prices to the farmers and 
maybe the farmers have (in their own interest) chosen to lock up the industry with regulation (and lobbying).

This is the sort of thing that is never spelled out in the accounts. After all if the company makes its profits by screwing the public it isn't going to tell you. [Unless they are United Airways who are just jerks.]

So without a detailed knowledge of the politics of rural Idaho I can't really analyse this situation. But hey - after reading this rather good book I know the questions to ask.

If anyone is really familiar with this oligopoly (particularly any potato farmers) I would really love to talk to you.

Till then I will just try to find another interesting book to read.


Wednesday, November 28, 2018

Afterpay: a regulator view

The Australian Securities regulator (ASIC) has come out with a long review of buy-now-pay later arrangements in which it has decided to do nothing monitor the companies going forward.

This is perceived by some as very bullish for Afterpay. The stock is up fairly hard as I write this.

Afterpay (ASX:APT) is the big player in this industry and a cult stock and cult product amongst Australian millennials. There are several other players and ASIC's study covered six of them.

ASIC does not have a reputation as an aggressive regulator so that they are monitoring the company going forward is the expected result.

But the ASIC report (available here) does give some insight into Afterpay.

Here are a few extracts:

First an example of underwriting:

Case study 1: Debts on top of further debts 
Vicki was in her early 20s and a mother to three preschool-aged children. She was unemployed but received Centrelink payments. 
Vicki had multiple payday loan debts totalling $4,000 and a $9,000 car loan. Vicki also had a $1,000 debt to Certegy Ezi-Pay that had been referred to a debt collector and several telecommunications and utility debts. 
Vicki explained that she then incurred a $740 debt to Afterpay to buy goods at a butcher and several clothing stores
Note that Afterpay is the last lender here and lent after a previous debt had been referred to a debt collector.

And another underwriting example:

Case study 3: Sold goods that the consumer didn’t need 
John received a carer’s pension. He was cold-called by a merchant who sold him a solar power system financed through Certegy Ezi-Pay. John said he did not have a job at the time and the salesperson said that he would write down John’s last job. 18 months later, he owed over $6,100. John also owed over $7,000 on a loan and $3,000 in other debt.
John said he started using Afterpay in early 2018 and now owes them $960. He said he doesn’t recall being asked about his expenses when he signed up for this arrangement.
Note again Afterpay is the last lender.

And another underwriting example:

Case study 4: No inquiries about the consumer’s financial position 
Ben was unemployed, received a disability support pension, and lived with his father who assisted him as a carer. Ben said he had a shopping addiction. 
Ben reported feeling overwhelmed with debt. He had a $5,000 credit card debt, and he was able to accrue a $1,500 debt with Afterpay, and a $1,000 debt with zipMoney.

In this case Afterpay lent after the consumer was clearly in trouble. But they may not have been the last lender.

Afterpay - the worst lender in the group

Afterpay is considered the gold standard in this sector. It has the most highly valued stock. I have asked several bulls and they all tell me how much better Afterpay is than the competition.

But ASIC have the numbers. Here is a graph of the percentage of Afterpay customers who incur a late fee versus the competition. It sure looks like Afterpay has the worst credit quality.

All I can say is that ASIC have helped out researching a controversial stock.


Monday, October 15, 2018

Schadenfreude: reposting a 2011 post on Sears

I posted on Sears in 2011

They finally filed bankruptcy.

I am surprised it took that long.

Here though is the post again. It reads okay.


We have been short Sears Holdings, publicly, albeit in small quantity. Being summer in Australia I did not even look at the market for the last couple of days - but got into work for some congratulatory emails as Sears stock is off very hard on an announcement of truly awful sales, the closure of 100 to 120 stores and $1.6 to $2.4 billion of non-cash charges. (More about the charges later on.)

I look pretty smart putting a Sears short on in November - and kudos is gratefully accepted but undeserved. I was short Sears at my old firm when the Eddie Lambert controlled K-Mart took them out for considerably more than they were worth. It was not the only time that happened to me - but multiple stabs don't dull the pain. I would gladly swap kudos for a refund of my then clients' money.*

The premise for owning Sears was property liquidation. The company owned many of its sites - sometimes on book at low historic values reflecting the company's long and once glorious history. Eddie Lambert and his merry-men were going to extract that value through selective store closures and super-profitable liquidation. Sears was an awful retailer (there was little doubt about that) but it was - they thought - a good property play.

My view: owning Sears as a property play is a demonstration of the arrogance and breathtaking naivete of much that passes on Wall Street. Sears Holdings has over 300 thousand employees. I don't know how you successfully liquidate a business integrated with that many lives. I don't know of anyone who has ever successfully liquidated a business with that many employees.** I am not sure it can be done and it certainly can't be done by someone with my skill-set (highly analytical, ability to spy value or value traps but no people management skill and not much tact).

The idea that Sears was going to be managed/liquidated by a bunch of hedge fund guys (people like me) well - that was comical.

Just to stress the point for my fund manager friends who read accounts and have my skills (but like me are often disconnected from the businesses they invest in) I will state the obvious. The employees are living breathing people and as you pull the business apart the way you treat those people and how they think about you (and behave towards you) are critical to any value you extract in liquidation. Someone has to look these people in the eye and tell them they don't have a job. And someone has to pick-and-choose which people to fire and which to retain. And they have to do this without destroying much of the value extracted along the way. They have to liquidate the firm in such a way that the value accrues to the liquidators and not to the people who are being screwed.

I don't care what you think of the morality of that. The reality of that is that it was always going to be hard - possibly very hard.***

We are about to find out how hard. Sears is going to close 100 to 120 stores (it is vague about the number) and fire many employees. But they have not worked out which employees or even which stores. Not to sound ghoulish - but my guess is that this is going to be considerably harder than the "Sears spokesman" makes it sound. And if they can't do 120 stores without trouble then the original Sears liquidation premise was insane. This is a case of Wall Street fantasy meeting reality: eventually reality wins.

The charges and reality

The large (non-cash!) charges deserve mention. This is from the Sears release:
[We Sears] expect that we will record in the fourth quarter a non-cash charge related to a valuation allowance on certain deferred tax assets of $1.6 to $1.8 billion
You know what that means. It means that you should not expect to earn that profit in the future. It is the admission from the Eddie Lambert controlled Sears that the fantasy is over.

The reality is unchanged: when you think of the 1950s you think of Sears. Sears was (in Main Street reality) irrelevant a decade ago. The Wall Street fantasy took a little longer to end.


*(A note about Schadenfreude.) The take-over of the old Sears by the Eddie Lambert controlled K-Mart was the second worst day of my career. The worst day was when Fred Goodwin's Royal Bank of Scotland purchased Charter One Financial. When I started the blog one of the main goals was to spell out just how atrocious Sir Fred Goodwin (the then CEO of Royal Bank of Scotland) was. The fourth post on this blog was the beginning of my "Sir Fred Goodwin death watch". I enjoyed watching him and his bank come apart. But I should not have enjoyed it. Schadenfreude is not an attractive personality characteristic and the collapse of RBS has caused real pain to a lot of innocent parties. And a Schadenfreudegasm - well that just strikes me as unreasonably indulgent. After all my clients lost money - and I should and would but cannot swap any pleasure I had for a refund of their losses.

This time though I am just accepting the Schadenfreude. My client are making money and I have no reason to feel guilty about that. Moreover I don't have to fire those employees. Unlike Royal Bank of Scotland (which Sir Fred destroyed) Sears employees were doomed anyway.

**. It is worth mentioning the GM example. GM was salvaged through bankruptcy with a couple of hundred thousand employees. But those employees were particularly trapped, the shareholders were wiped out and the Government contributed considerable money. That is what a "successful" transition for a business with that many employees looks like.

***. (Politics, employees and realism). I am a bleeding heart left-winger and naturally feel a little paternalistic to the employees being fired. However you don't need to be a bleeding heart lefty to agree with my analysis. A realist will tell that when you have 300 thousand employees your relation to them is going to be critical in running your business. Employees are "stakeholders" even if your only (moral) criteria is "shareholder value". Realism over politics is a better basis for investment.

Monday, October 1, 2018

The last day of the quarter (Tesla edition)

Hedge fund managers who actively trade to produce profit specifically on the last day of the quarter should be treated with scorn. They are marking their book and that is bullshit.

It doesn't mean that it doesn't happen. Just treat it with the contempt it deserves.

Companies that do things to produce results on the last day of the quarter should be treated with similar scorn. Channel stuffing, shifting expenses into the next quarter and other forms of abuse lay there.

I am completely staggered by an SEC filing by Tesla today detailing an email by Elon Musk to staff. I will quote in full:

EX-99.1 2 tsla-ex991_6.htm EX-99.1
Exhibit 99.1 
The following e-mail was sent by Elon Musk to all employees of Tesla, Inc. on September 30, 2018.

We are very close to achieving profitability and proving the naysayers wrong, but, to be certain, we must execute really well tomorrow (Sunday).

If we go all out tomorrow, we will achieve an epic victory beyond all expectations.

Go Tesla!!!

Thanks for all your hard work,

If this were a drug company I would call fraud. Channel stuffing is just too easy.

But this is a car company and channel stuffing doesn't work so well.

I am wondering (comments please) on just what Tesla could possibly be doing on a Sunday, the last day of the month, to produce the result Elon desires?


and hat-tip to Jaguar Analytics for pointing out the filing...

Monday, September 17, 2018

Crypto Pot Stock

There is a point in the cycle when it is impossible to separate comedy from stock promotion.

Examples in the past:

But now the promotes are crypto and marijuana. So I give you this from a genuine promotional email. I could not make this up. Needless to say I do not recommend buying this stock.

ATTBF Is The ONLY Cannabis-Crypto Stock
YOU Need To Watch On Monday!
Dear Fellow Traders,

My New “Crypto Pot Stock” Alert for Monday is: ATTBF

ATTBF Joins The Crypto Revolution!!!

‘Cannabis + Crypto.’ The two single HOTTEST Sectors of the Market right now.

ATTBF is now merging the two together, and the windfall could be tremendous.

On Feb 1, the company announced the Acquisition of a 49% Stake in CannaNUMUS Blockchain Inc. - developers of a cryptocurrency which will represent the performance of a suite of portfolio cannabis companies.

“With a 49% equity stake in this blockchain platform, Abattis could see a significant upside from any CannaNUMUS liquidity event, including a reverse take-over of CannaNUMUS or an ICO,”

Yes, there are already Marijuana-based CryptoCurrencies. And while none are especially noteworthy, it's worth mentioning that CANN(CannabisCoin) has seen 20,000%+ GAINS and now boasts a $5.5 MIL Market Cap, POT (PotCoin) has seen 3,300%+ GAINS and enjoys a $35 MIL Market Cap, and THC (HempCoin) has seen a monsterous 114,000%+ Gain with a $28 MIL Market Cap!

Needless to say, ATTBF is in good company!


Wednesday, September 5, 2018

Thinking aloud about China Biologic Products

There are stocks which you never get right - and where the facts and history is just so ambiguous that you don't think you will ever get them right.

China Biologic Products (Nasdaq:CBPO) is one of those that leave me perplexed. It is a blood processor in China with a strange political and arguably unsavoury past followed by years of spectacular performance and a few failed takeover bids.

I am short. And I think now I have probably made a little money - but hardly enough to justify the stress I have gone through. And after all this time I am still far from sure what the underlying reality is.

So I will lay out what I know and what I think I know.

The creation of China Biologic Products and the arrest and imprisonment of Dr Du

Australia has a long history in blood processing to provide antivenoms and technical blood products and has produced a global-giant product in this space - CSL. Dr Du was a Melbourne based Chinese heart and lung surgeon with good knowledge of this technology who moved to China to start a blood processing business which was by repute not very large, but modestly successful.

It didn't end well for Dr Du. He was arrested and charged with embezzling a couple million yuan from the company (the accuser was his business partner) and the business was stripped from him. He spent six years in prison. You can find an abbreviated version of the story here.

There is some evidence that these charges were trumped up. And they were not over a lot of money in the scheme of things. The amount of money was USD360 thousand. This is not how a giant and successful business usually changes hands.

The reverse merger of China Biologic Products

China Biologic Products came to market by the most suspect of methods - a reverse merger - at the height of the China reverse merger frauds. The material here looks really damming. Here is the first 10-K filing by the company as a Chinese company.

China Biologic Products, Inc. was originally incorporated on December 20, 1989 under the laws of the State of Texas as Shepherd Food Equipment, Inc. On November 20, 2000, Shepherd Food Equipment, Inc. changed its corporate name to Shepherd Food Equipment, Inc. Acquisition Corp., or Shepherd. Shepherd is the survivor of a May 28, 2003, merger between Shepherd and GRC Holdings, Inc. or GRC. In the merger, the company adopted the Articles of Incorporation and By- Laws of GRC and changed its corporate name to GRC Holdings, Inc. On January 10, 2007, a Plan of Conversion became effective pursuant to which GRC was converted into a Delaware corporation and changed its name to China Biologic Products, Inc... 
On July 19, 2006, we completed a reverse acquisition with Logic Express, whereby we issued to the stockholders of Logic Express, 18,484,715 shares of our common stock in exchange for 100% of the issued and outstanding shares of capital stock of Logic Express and its majority- owned Chinese operating subsidiary, Shandong Taibang. As a result of the reverse acquisition, Logic Express became our 100% owned subsidiary and the former shareholders of Logic Express became our controlling shareholders with 96.1% of our common stock. Shandong Taibang became our 82.76%- owned indirect subsidiary and is the operating company for all of our commercial operations. Shandong Taibang, is a sino-foreign joint venture company established on October 23, 2002 with a registered capital of RMB80 million (approximately $10.3 million). Upon the closing of the reverse acquisition, Timothy P. Halter, our sole director prior to the reverse acquisition, submitted his resignation letter pursuant to which he resigned from all offices he held and from his position as our director, effective immediately. Siu Ling Chan and Lin Ling Li were appointed as our directors at the closing of the reverse acquisition. In addition, our executive officer was replaced by the Logic Express executive officers named herein at the closing of the reverse acquisition.
There is a fair bit to unpack here. The listing was a standard enough reverse merger into Shepherd Food Equipment Acquisition Corp. You would like to find something out about them but they were an utterly delinquent filer. SEC filings don't exist.

And the core business wasn't China Biologic Products (that name came later). It was Shandong Taibang. Moreover they only owned after the merger 82.76 percent of it. The other 17.24 percent was owned by an undisclosed party. That party will be explored later in this note.

Finally the vendor of the shell was Timothy P. Halter. He was ground zero for literally dozens of disastrous Chinese reverse mergers as per this 2011 Reuters article.

The entity actually reverse merged into China Biologic Products was called Logic Express, a British Virgin Islands Company. I do not know how Logic Express acquired Shandong Taibang. The deal happened on 19 July 2006.

We know a little more about Logic Express now than when this deal happened because of the leak of the Panama Papers. Here is the link to Logic Express in the Panama Papers. Logic Express was registered on 6 Jan 2006, just over six months before it went public and originally had only two shareholders. These were Chan Siu Ling and Li Lin Ling. Three more shareholders signed up on 11 July 2006 - a mere 8 days before the company was listed.

These shareholders were granted 18,484,715 worth about $1.8 billion dollars at current price. And remember what they owned was 83 percent of Shandong Taibang - founded only in 2002 and with registered capital of about USD10 million.

The two shareholders prior to the reverse merger

The Panama Papers list only two shareholders of Logic Express from inception. They are Chan Siu Ling and Li Lin Ling. Who are they? Well let's get back to them later.

The reverse merger press release

There was a press release to announce the reverse merger. You can find the original at this link, but here it is almost in its entirety:

SHANDONG, China--(BUSINESS WIRE)--July 20, 2006--Shandong Missile Biologic Products Co. Ltd. ("Shandong Biologic"), announced today the closing of a reverse merger transaction with GRC Holdings, Inc. (OTCPK:GRCG) ("GRC") and the closing of an equity placement by GRC and certain of its controlling stockholders raising $8.1 million in aggregate gross proceeds. Shandong Biologic is a biopharmaceutical company principally engaged in the research, production and manufacturing of human plasma-based pharmaceutical products in the People's Republic of China ("China"). GRC is a publicly-held, non-operating company with headquarters in Argyle, Texas that is in the process of changing its name to China Biologic Products, Inc.  
The reverse merger transaction involved a stock exchange with the stockholders of Logic Express Limited, a British Virgin Islands company ("Logic Express"), the 82.76% owner of Shandong Biologic. Upon closing of the exchange transaction , Logic Express became a wholly-owned subsidiary of GRC and the former shareholders of Logic Express acquired approximately 96% of GRC's issued and outstanding common stock immediately prior to the financing transaction described below. 
In connection with the change in ownership of GRC, Ms. Katherine Loh, Ms. Lin Ling Li and Ms. Siu Ling Chan were appointed to the Board of Directors of GRC, Mr. Michael Li was appointed as its Chief Executive Officer and Mr. Peter Yeung was appointed as its Chief Financial Officer. 
Immediately following the exchange transaction, a private placement of shares of common stock closed involving the issuance by GRC of 2,200,000 shares of its common stock at a purchase price of $1.895 per share and warrants to purchase 1,070,000 shares of common stock at an exercise price of $2.8425 per share. In addition, two of the controlling shareholders, Siu Ling Chan and Lin Ling Li (the "Selling Shareholders"), sold an aggregate of 2,080,000 shares of GRC common stock at a price of $1.895 per share to the investors including Pinnacle China Fund, L.P., who acted as lead investor in the private placement. Lane Capital Markets acted as exclusive placement agent and financial advisor and received warrants to purchase 214,000 shares of common stock at an exercise price of $2.8425 per share. As a result of the forgoing transactions, the investors collectively hold approximately 20% of GRC's issued and outstanding common stock immediately after the completion of the private placement but before the exercise of the warrants. 
Gross proceeds from the investors amounted to approximately $8.1 million. Part of the proceeds to GRC will be used to meet a $3.3 million capital contribution requirement that Logic Express has in Shandong Biologic. The proceeds being received by the Selling Shareholders will be placed into escrow until registration of the capital contribution with the PRC authorities is complete and, upon release, will be used primarily to repay indebtedness owed to Shandong Biologic. In the event such registration is not completed by July 31, 2006, the proceeds will be refunded to the investors and the shares purchased returned to the Selling Shareholders.
As part of the private placement transaction, the Selling Shareholders have placed an aggregate of 4,280,000 shares of common stock into escrow. If the audited consolidated financial statements of GRC do not reflect at least $4,819,500 of after-tax net income or $5,823,465 of after-tax net income before minority interest for the fiscal year ending December 31, 2006, one-half of the escrow shares will be distributed on a pro rata basis to the investors. If the audited consolidated financial statements of GRC do not reflect at least $8,302,000 of after-tax net income or $10,031,416 of after-tax net income before minority interest for the fiscal year ending December 31, 2007, the second-half of the escrow shares will be distributed on a pro rata basis to the investors. If GRC has met the applicable threshold, the appropriate number of escrow shares shall be returned to the Selling Shareholders. GRC estimates the 2006 and 2007 revenues, on a consolidated basis, to be approximately $22 million and $36 million, respectively. The Company emphasizes that the foregoing revenue estimates constitute forward-looking statements, and actual results may be materially different from those expressed herein.

Again it is worth unpacking details here.

The reverse merger target was in Argyle Texas. This isn't exactly a big place. The population is a couple of thousand. It is however where the above mentioned Timothy Halter has his ranch and many of his other reverse mergers hailed from. The company traded before (and after) this transaction on the Pink Sheets.

Peter Yeung (who first turned up as a shareholder only 8 days before the reverse merger transaction) is the foundation Chief Financial Officer. But whoever Peter Yeung is he did not stay as Chief Financial Officer very long. The first 10-Q for China Biologic Products refers to Stanley Wong as Chief Financial Officer. I have tried to find out what happened to him. The best I have found is that he is Canadian educated and he handled the reverse merger as per this Bloomberg link.

The Bloomberg link also states that Peter Yeung is also known as Wai Keung Yeung. An Albert Yeung (also sometimes Wai Keung Yeung) reappears on the board in 2012 as an independent shareholder even though the lineage appears to be as a director of the pre-reverse merger BVI company.

Also in this transaction the company issued 2,200,000 shares of its common stock at a purchase price of $1.895 per share and warrants to purchase 1,070,000 shares of common stock at an exercise price of $2.8425 per share. The insiders also sold 2,080,000 shares of GRC common stock at a price of $1.895. (With the shares at about $90 that does not look like a great insider sale!)

The only named investor was Pinnacle China Fund. That is Barry Kitt's outfit. Mr Kitt is a controversial figure from the world of Chinese reverse mergers as this old Barrons piece shows. However in this case Mr Kitt's shares would be up a few hundred million dollars. Perhaps he is a great investor after all.

The final thing is that the reverse merger agreement contained a collateralised guarantee that the published accounts will show at least a certain amount of profit - at least $10 million before minority interests. Remember that the capital base of Shandong Biologic was prior only about $10 million. These are big guarantees. But they were met. However the whole thing seems a little irrational. If China Biologic could really earn that much why were insiders selling their own shares to Barry Kitt's group? I couldn't explain it.

My being puzzled

China Biologic Products looked like a classic 2011 period Chinese reverse merger promotion. There are some of  the same players as many of the entities that failed during that period.

But there was one big difference. A deciding difference. And that was the business founded by Dr Du. I sounded out several people who knew Dr Du. One was a journalist who followed the story. One was a former official of the (Australian) Department of Foreign Affairs who had paid consular visits to Dr Du when he was an Australian in a Chinese prison.

All of these people described Dr Du as legitimate and the business he operated as a real and valuable operation. This differed from some of the more egregious 2011 era Chinese reverse mergers because there was something there.

We were short it in those days. And we covered. And thank the Dear Lord we did because the stock is up over 10x since we covered.

It was always a possibility that some real Chinese companies chose to list into defunct pink-sheet shells and wind up being a fantastic business. And I guess this was that.

The recommendations I got for Dr Du and his business were universally good. This may well be a truly good business that came to the market in an unusual way.

Just how good?

Well to say China Biologic Products did well is to understate it. Here it is graphed against Google and Amazon as far back as Yahoo! has the data.

You see that - it is almost as good as Amazon, and was way better early-on. And both of those make Google look like a stock for losers. (As I own Google and not Amazon or China Biologic I am suitably chastened.)

Whatever: it is an astonishing performance.

And it is a performance reflected in the accounts. They are frankly amazing. Here are the accounts downloaded from CapitalIQ. According to the accounts this has generated substantial net cash every year and capital expenditures have never exceeded $50 million. This company has grown like a weed and has never appeared to need external money. On the accounts this is an amazingly good business.

The company did a few acquisitions to increase their footprint but in aggregate there were not many.

The company generated plenty of cash - but it did not pay dividends or buy back stock. Indeed they issued stock. As of the last balance sheet they were sitting on $366 million in cash and securities mostly representing past profits. Remember very little cash was ever actually deployed in this business.

Along the way there were repeated transactions with PW Medtech - a fairly illiquid Hong Kong listed company who seems to me to be functionally a related party. PW Medtech owns 5.5 million CBPO shares which is considerably more than its market cap. It has also - according to accounts and press releases received considerable cash. Marc Chan owns over a quarter of PW Medtech and 7 percent of CBPO. He may not technically be a controlling person - but he clearly has a large position. He never appears on any board though he is seemingly a Hong Kong resident operating through several BVI companies such as Parfield International.

Executives and associated people

It is hard to find career details for executives of this company - but here are a few that I have puzzled over.

Stanley Wong

The first 10-Q names Stanley Wong as CEO. You can find his LinkedIn page here. I have kept an archive of it here. The LinkedIn CVs states his role was "listing work". However he was there for ten months. He has been a director of a few companies that worked and a few that didn't. CapitalIQ for instance lists him as a former director of Blockchain Group (HK:0364). That didn't work.

Tung Lam

The first 10-K the company lists Tung Lam as the chief executive of the operating subsidiary:
Tung Lam. Mr. Lam has been the Chief Executive Officer of our operating subsidiary, Shandong Taibang, since October 2003, and is responsible for the entire operation. Prior to joining the Company, Mr. Lam served, from November 1999 to August 2003, as the vice president of Fujian Province Fei Yue Group, where he was in charge of management investment.
It also states that:
Ms. Siu Ling Chan is the wife of Mr. Tung Lam.
You will remember her as one of the shareholders of Logic Express prior to its reverse merger. I am trying to establish if she is related to Marc Chan from PW Medtech - but have made no progress.

The 10-K also gives a CV for Ms Chan.
Siu Ling Chan. Ms. Chan has been our director since July 19, 2006. She has been our chairwoman since January 1, 2007 and served as our CEO from January 2007 to March 2007. Ms. Chan is also currently a director of our subsidiary Logic Express. She was also appointed as the director of Shandong Taibang in April 2006. Prior to joining us, Ms. Chan worked from 1991 to 2005, as an administrator at the Fujian Academy of Social Sciences, and from 1989 to 1991 as a statistician at the Fujian Pingtan Economy Committee. She received her diploma in Statistics from Xiamen University in 1989 and a diploma in management from the Fujian Party Committee School in 2004.

The important detail is that she was educated at a Party School. These are finishing schools for elite Communist Party cadres.

In 2010 China Biologic responded to on-line claims that it was a criminal fraud. The company set up a special committee to investigate and they in turn selected O'Melveny & Myers LLP to advise them. The Special Committee report is summarised in an SEC filing which you can find here. The Special Committee squibbed on the issues associated with Tung Lam. To quote:

Allegations Regarding Identity of Tung Lam – With respect to the allegation that Mr. Tung Lam, the Chief Executive Officer of one of the Company's primary operating subsidiaries, Shandong Taibang, and spouse of Mrs. Siu Ling Chan, the Company's board chair, was previously known as Mr. Lin Ziping and was imprisoned for smuggling in China, the Special Committee found evidence supporting Mr. Lam's denial of the allegation, as well as conflicting evidence with respect to this claim. As a result, the Special Committee concluded that it could neither confirm nor exclude the allegation.
Ze Qin Lin

The special committee did not squib on the husband of the other original shareholder of Logic Express. Here is what they have to say:
Allegations Regarding Ze Qin Lin – With respect to the allegations that Mr. Ze Qin Lin, the husband of current CBPO director Ms. Lin Ling Li, is a former associate of Mr. Tung Lam and was imprisoned in China in connection with the same smuggling activities, the Special Committee found support for the allegation that Mr. Ze Qin Lin was sentenced to imprisonment in China in connection with smuggling offenses of Fuzhou Bonded Zone Western Industrial, Ltd.
In fairness China Biologic also has other directors and officers whose CVs seem entirely appropriate. Many are hard to trace but that is probably my unfamiliarity with the Chinese sources.

The simple product list

One of the interesting things about this company is how far and fast it has grown despite an extremely limited product set none of which are patent protected and all of which have extensive competition. There are only nine products sold in different dose forms as per this extract from the last annual report.

We have a strong product portfolio covering over 20 different dosage forms of plasma products across nine categories, and one chemical drug, placenta polypeptide. All of our plasma products and the placenta polypeptide product are prescription medicines administered in the form of injections. Our principal products are human albumin and immunoglobulin for intravenous injection, or IVIG. Albumin has been used for almost 50 years to treat critically ill patients by assisting the maintenance of adequate blood volume and pressure. IVIG is used for certain disease prevention and treatment by enhancing specific immunity. These products use human plasma as their principal raw material. Sales of human albumin products represented approximately 35.8%%, 39.2% and 37.6% of our total sales for 2017, 2016 and 2015, respectively. Sales of IVIG products represented approximately 31.7%, 34.6% and 42.2% of our total sales for 2017, 2016 and 2015, respectively.
The breakdown of sales is given in the following chart:

Human albumin - their biggest product - is the most widely produced blood fraction in the world. Intravenous immunoglobulin (IVIg) is also very widely produced. The same can be said of all nine products - things like Rabies antibodies (which regular readers will know I have had).

The last corporate presentation also makes clear that the company has a low market share - singled digit in most products. Here is the key slide.

In human albumen, their biggest product, the market share is below 6 percent.

Ignoring this company

I shorted this company in 2011 along with a bundle of Chinese reverse mergers. The aggregate trade was great - but this stock went up and I covered. I am not a sucker for endless pain.

Moreover I heard pretty good things about the business Dr Du established. And so what I had was:

a) evidence from people who knew the founder that this was a good business
b) a path to market associated with a raft of corporate failures and shareholder losses
c) world beating high levels of profitability despite low market share in commodity products
d) reams of related party transactions (especially if you regard PW Medtech as related).

All of this makes for something that interests a short-seller but I wasn't going to put my neck on the line and short a stock that was performing like Amazon without stronger evidence and a catalyst.

So I passed. I just kept a watching interest. But the right position was in my opinion to be flat. (In retrospect I should have been long - but the rectrospectoscope is 20/20.)

Inventories: the odd part of the accounts

There was one anomaly in the accounts - one that I kept coming back to. This company seems to have too much inventory. This is particularly pronounced in the company's latest presentation.

The presentation continuously points to supply shortages for plasma and blood products. For example take this slide which I have highlighted.

Despite repeated comments by the company of shortages the inventory days are large and growing. This slide from the same presentation shows inventory days at 589. And it is not as if there is a complicated set of products which need to be held. There are only nine products and a range of doses. Again I have highlighted the key section.

Blood products have large inventories. You need a store for emergency, and the time, for instance, for all the tests to come back also adds to the number of inventory days. The two biggest blood processing companies (CSL, Grifols) have between 230 and 260 days inventory.

China Biologic has an extra year or it sitting around.

Some of the Chinese companies have more inventory than this - but none has close to China Biologic.
  • Shanghai RAAS Blood Products Co (listed as a large competitor) has 197 days as of 30 June 2018,
  • Hualan Biological Engineering has 425 days as of 30 June 2018,
  • Shenzhen Weiguang Biological Products also has 425 days as of 31 December 2017
  • Boya Bio-pharmaceutical Group has 229 days as of as of 30 June 2018

I have identified private companies in the space too - and all have less inventory days than China Biologic. You can find our source list here. However we count CBPO has anomalously large inventory.

I presume it is in fridges and well preserved or otherwise it would stink.

Whatever. It is hard to reconcile all those excess inventory days with the repeated claims of shortages of product.

The takeover bid and overbid and eventual share placement

Eventually the company received a go-private bid and an overbid. The first bid was from CITIC which is the government controlled Chinese private equity firm. CITIC is "Princeling Central" - the place where the children of the most powerful cadres wield their stuff.

Here was the bid. Note that it is non-binding and subject to due diligence.

BEIJING, June 19, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ : CBPO ) ("CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has received an unsolicited, preliminary non-binding proposal letter from CCRE Holdings Limited, a wholly owned subsidiary of CITIC Capital Holdings Limited (together with its affiliates, "CITIC"), pursuant to which CITIC proposes to acquire all of the outstanding shares of the Company not already owned by CITIC for US$110 in cash per share... 
The Board cautions the Company's shareholders and others considering trading in the Company's securities that the Board is reviewing and evaluating CITIC's proposal and no decisions have been made with respect to the Company's response to the proposal. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.
So I am still completely unsure about China Biologic Products. It may be one of the greatest companies ever (as the accounts indicate) but I can’t dismiss the possibility that it is a residual Chinese reverse merger stock promote that did not fall apart around 2011. I know there is a business there - and probably a good business there - the one founded by Dr Du. But that this business has massively outperformed Google seems to me a stretch.

Anyway - I thought now I get a cheap look. CITIC would get to due diligence on this company and would find out. If they did they would either:

(a) buy it and I would lose my spread or
(b) walk away, sell their stake (possibly aggressively) and I would make some coin.

I genuinely had no idea of the outcome - but I thought the risk-reward was favourable so I put on the short.

I got a little lucky. There was a vaccine scandal in China after I put the position on. One of the tainted products was rabies antibodies - a direct competitor to China Biologic. At a minimum fairly heavy regulation is coming. Xi commented extensively and was clearly angry. And when the Supremo is angry with blood products and vaccines a risk averse organisation like CITIC buying in seemed unlikely.

Here are a few Xi quotes - as per the South China Morning Post...

“The violations by Changchun Changsheng Bio-technology are serious and appalling,” state broadcaster CCTV quoted Xi as saying... 
Xi also ordered the authorities to use severe punishment “to cure the chronic disease [of corruption] and scratch poison from one’s bones”. 
He told the authorities to resolutely “improve the supervision of vaccines and guard the bottom line of safety in order to safeguard public interest and social security”.

I just did not think the deal would close. And for that matter nor did the market as the spread widened.

Then China Biologic received an overbid...

BEIJING--(BUSINESS WIRE)-- A consortium composed of Mr. David (Xiaoying) Gao, GL Capital Group, Bank of China Group Investment Limited and CDH Investments (the “Consortium”) today announced it has made a non-binding proposal to acquire all of the outstanding common shares of China Biologic Products Holdings, Inc. (“China Biologic” or the “Company”) (NASDAQ: CBPO), that are not already held by the Consortium, for US$118.00 per share in an all-cash transaction valued at approximately US$3.9 billion. The proposal was conveyed on August 17, 2018 in a letter to China Biologic’s Board of Directors. 
The Consortium’s proposal represents an approximate 30% premium to China Biologic’s closing share price on August 16, 2018, and an approximate 40% premium to the Company’s closing price on June 8, 2018, the last trading day before CITIC Capital’s proposal to acquire the Company for US$110.00 per share was conveyed.
Commenting on its offer, the Consortium stated: “Our proposal delivers immediate and attractive value to China Biologic’s shareholders and provides the Company the ideal partners to support its future growth. As a private company, China Biologic will have the additional operational flexibility and financial support to build on its successful track record as China’s leading plasma player while navigating the current challenges facing the country’s biopharma industry.” 
“Our compelling proposal benefits all of China Biologic’s stakeholders and we want to work collaboratively with the Board to complete a transaction in an efficient and expeditious manner. We also want to partner with the current management team as we take the Company forward.” 
The Consortium has received from Goldman Sachs (Asia) L.L.C. (“Goldman Sachs”) a non-binding letter indicating that, subject to the assumptions, terms and conditions in the letter and such other matters as Goldman Sachs considers relevant, Goldman Sachs is, as of the date of the letter, highly confident that as sole lead arranger, sole bookrunner and sole syndication agent, the structuring and syndication of a senior secured debt financing could be accomplished by Goldman Sachs as part of the financing for the acquisition described therein. 
Goldman Sachs is acting as financial advisor to the Consortium, Skadden, Arps, Slate, Meagher & Flom LLP is acting as its U.S. legal advisor, and Conyers, Dill & Pearman is acting as its Cayman Islands legal advisor.
At this point I thought I was probably toast. David Gao is a former CEO of the company and so presumably knows what he is buying. His CV is plausible though it contains blemishes. The most notable blemish is that he was on the board of ChinaCast Education - a reverse merger stock that collapsed with admitted fraud. Moreover Goldman Sachs was highly confident that this could be financed.

I simply couldn't see how I could win. But then I was puzzled because the vaccine scandal in China was growing. I could not see how the deal made sense with a wave of re-regulation coming at them.

Whatever. I was let off the hook. China Biologic rejected both bids without due diligence and took money from a consortium to finance their future growth. Here is the press release.

BEIJING, Aug. 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company's board of directors (the "Board") has received a letter dated August 23, 2018 from CITIC Capital MB Investment Limited, an affiliate of CITIC Capital Holdings Limited ("CITIC"), withdrawing its preliminary non-binding proposal dated June 11, 2018, with immediate effect. The Company further announced that the Board has unanimously decided to reject the previously announced preliminary non-binding proposal dated August 17, 2018 from the consortium (the "Consortium") consisting of Feng Tai Global Limited, a company beneficially owned by Mr. David (Xiaoying) Gao, the former Chairman and CEO of the Company, GL Sandrose Investment L.P., World Investments Limited and CDH Utopia Limited. 
After careful review of the Consortium's proposal, the Board has unanimously determined that it is not in the best interests of the Company and its shareholders as it did not reflect the intrinsic value of the Company and would abrogate the shareholders' opportunity to enjoy the long-term return from the Company's execution of its business strategy of growing into a leading global biopharmaceutical company. 
In addition, the Company announced that it has entered into definitive agreements (the "Share Purchase Agreements") for the issuance and sale of an aggregate of 5,850,000 ordinary shares of the Company, which represents 14.9% of the enlarged share capital post the issuance and is expected to raise gross proceeds of approximately US$590 million. The Company intends to use such proceeds to support its business expansion plan and strategic acquisitions. Under the Share Purchase Agreements, Centurium Capital Management Ltd. ("Centurium"), CITIC, Hillhouse Capital Management, Ltd. ("Hillhouse"), each via its respective investment vehicle(s), and PW Medtech Group Limited ("PWM", and together with Centurium, CITIC and Hillhouse, the "Investors") will subscribe for and purchase 3,050,000, 1,000,000, 1,000,000 and 800,000, respectively, newly issued ordinary shares of the Company at a per share purchase price of US$100.90, representing the closing price per share as quoted by the NASDAQ Global Market on August 23, 2018, and a premium of 2.5% and 7.9%, respectively, over the Company's 30 and 90 trading day volume weighted average price as quoted by the NASDAQ Global Market through August 23, 2018.

The release is a doozy. The company is rejecting the offer from the previous CEO. CITIC is withdrawing its offer and they are issuing 5.85 million shares to raise $590 million from a group of respectable investors.

The big buyer is PW Medtech - and it is really hard to understand how they subscribe to this. PW Medtech has a market cap of USD320 million and it is buying over $300 million worth of stock. Their accounts show 90 million yuan of cash. That doesn't come close to paying for this. And - as observed - they and their controller - the difficult to track Marc Chan - are already massively overweight China Biologic.

The other buyers are CITIC and Hillhoue. Hillhouse is only in for $80 million which to them is a drop-in-the-ocean. I know some senior people at Hillhouse. I had lunch with them once. But they haven't answered my emails. I am really keen to find out what they see in this company that I have missed.

But at the end of this I am just perplexed. Yeah I am staying short. I don't see how all this works. But then again Dr Du did - by repute - found a pretty decent business so anything is possible.

Dear readers I would love your thoughts. And if someone with a contrary view on the stock wants to contact me I am keen. Hillhouse presumably believes the extraordinary growth this company has had can continue. I would love to chat to them.

Till then yours in puzzlement. Oh, and I remain short, but less short than when the takeover was in full swing.


Saturday, September 1, 2018

How the Chinese business elite think of America...

China Properties Group is a Hong Kong listed property developer with operations in Shanghai, Beijing and Kunshan. The business conditions description in the last interim report gives a reasonable appraisal of what the Chinese business elites think of America.

To quote:

Business Review and Outlook 
10 years ago, the U.S. printed money like crazy and exported U.S. dollars all over the world. Now, the U.S. has become a global enemy, trying to bring back the exported U.S. dollars (the U.S. dollar debt of the emerging market in the first quarter was close to 3.7 trillion) and supply chains, as well as to undermine the asset markets of other countries and the global supply chain order. No wonder the U.S. has made a lot of enemies. Fortunately, Trump does not have the same wisdom as Mao Zedong in making alliance with one while fighting another. He wants to fight the world. But to defeat the U.S. hegemony is not an easy task. The history told us that those who wanted to kick out the big brother would run the risk of being wiped out. Nevertheless, Chinese are savvy and resourceful. Deng Xiaoping said, “we should grope our way across the river, going one step at a time”. Jiang Zemin said, “keep a low profile to make a big fortune”. Han Xin demonstrated his immense ability to endure humility in order to preserve his existence for future accomplishments. Such wisdoms contributed to the creation of incredible historical achievements one after the other. Today, the U.S. is pushing the trade war to the limit. Yet, it is not easy to cripple the China model, even with Trump’s wisdom. With a looming war, there are risks as well as opportunities. Therefore, the Group’s established policies will remain unchanged. While some projects are delayed pending for the government’s new plan, the Group will always ensure that Shareholders’ benefits are well taken care of.
As always,


Monday, August 13, 2018

Dear Bayer shareholders, what are you thinking?

Bayer is a life-sciences company. It sell drugs with litigation risks (especially Xarelto), it genetically modifies seeds (which I guess has litigation risks). It sells herbicides and pesticides all of which have litigation risks.

If you do "life sciences" you muck around with living things and that has litigation risks.

On twitter recently I sought out discussion on risks of Bayer stock and litigation was the key one.

Today Bayer stock is down 12 percent on a California court case where a dying plaintiff claimed that roundup caused his cancer and a jury agreed.

The damages were set at $289 million.

Having watched lots of legal stuff in American stocks I would be surprised if this were not rounded down at least 90 percent on appeal, and if the agglomeration of future cases didn't cost a lot of money.

But whatever. Here is a list of the biggest class actions in US history. None break $10 billion except the global tobacco settlement.

The biggest aggregate claim I can remember is fen-phen which wound up costing about $13 billion.

All of these are spread over many years. And are tax deductible to boot.

Today Bayer's market cap dropped $14 billion, bigger than the biggest set of (non-tobacco) legal losses in history.

This seems disproportionate to me - but then I own Bayer stock. And I am puzzled.

So I am asking the people trading it in Germany - why are you so pessimistic about this?

I genuinely want to know.


Wednesday, August 8, 2018

Dear Michael Clarke, there are worse things you can do than tamper with the ball using sandpaper

Note, as of 20 October the crypto-currency referred to in this blog post is no more and Michael Clarke has dissociated himself from this crypto-currency.

The following appears on their website:

We would like to inform you that the Global Tech Exchange’s (‘Global Tech’) Initial Coin Offering (ICO) has now ceased in accordance with ASIC requirements.
As a result of this Global Tech has issued full refunds to all investors. If you have invested with Global Tech and have not yet received a refund please contact 
We would also like to inform you that Michael Clarke is no longer associated with Global Tech Exchange and the Global Tech Exchange Blockchain education and awareness program. 
Global Tech would like to inform you that it wishes to comply with all of ASIC’s requirements and requests, to the best of it’s ability.

Original post 

Michael Clarke, the former Australian Cricket Captain, must have fallen on hard times.

He is here - late cycle - squandering his reputation on an initial coin offering.

His twitter stream contained the following amazing tweet:

Whether Michael Clarke is breaking Australian law regarding advertising investments with this tweet I will leave for ASIC and their lawyers to decide. But it is pretty darn gutter thing to do with your reputation.

And dear Mr Clarke, cricket is a game where fair play is central. You are tossing your reputation just as surely as if you used sandpaper on the ball.

Which of course your successor as Australian cricket captain did.

Still, when your error was pointed out you just blocked me on Twitter.

Steve Smith at least had the decency to appear contrite.

I will be less forgiving of you.


PS The ICO says on its website that is "Austrac approved". Austrac is the Australian anti-money laundering authority.

Mr Clarke, are you confident endorsing that claim?

PPS. For my many readers from non-cricket playing countries, have a look at the amazing press conference when Steve Smith, Australian Captain, was caught cheating.

I wonder if Mr Clarke will have that decency.


General disclaimer

The content contained in this blog represents the opinions of Mr. Hempton. You should assume Mr. Hempton and his affiliates have positions in the securities discussed in this blog, and such beneficial ownership can create a conflict of interest regarding the objectivity of this blog. Statements in the blog are not guarantees of future performance and are subject to certain risks, uncertainties and other factors. Certain information in this blog concerning economic trends and performance is based on or derived from information provided by third-party sources. Mr. Hempton does not guarantee the accuracy of such information and has not independently verified the accuracy or completeness of such information or the assumptions on which such information is based. Such information may change after it is posted and Mr. Hempton is not obligated to, and may not, update it. The commentary in this blog in no way constitutes a solicitation of business, an offer of a security or a solicitation to purchase a security, or investment advice. In fact, it should not be relied upon in making investment decisions, ever. It is intended solely for the entertainment of the reader, and the author. In particular this blog is not directed for investment purposes at US Persons.